PT  - JOURNAL ARTICLE
AU  - Polimanti, Renato
AU  - Levey, Daniel F.
AU  - Pathak, Gita A.
AU  - Wendt, Frank R.
AU  - Nunez, Yaira Z.
AU  - Ursano, Robert J.
AU  - Kessler, Ronald C.
AU  - Kranzler, Henry R.
AU  - Stein, Murray B.
AU  - Gelernter, Joel
TI  - Complex multi-environment gene interactions linked to the interplay between polysubstance dependence and suicidal behaviors
AID  - 10.1101/2020.01.14.20017509
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.01.14.20017509
4099  - http://medrxiv.org/content/early/2020/01/18/2020.01.14.20017509.short
4100  - http://medrxiv.org/content/early/2020/01/18/2020.01.14.20017509.full
AB  - Background and Aims Substance dependence diagnoses (SDs) are important risk factors for suicidal behaviors. We investigated the associations of multiple SDs with different suicidal behaviors and tested how genetic background moderates these associations.Design Multivariate logistic regression to investigate the associations of SDs with suicidal behaviors; structured linear mixed model to study multivariate gene– environment interactions.Setting The Yale-Penn cohort was recruited to investigate the genetics of SDs. The Army STARRS (Study to Assess Risk and Resilience in Servicemembers) cohort was recruited to evaluate mental health risk and resilience for suicidal behaviors among Army personnel.Participants Yale-Penn participants (N=15,557) were assessed via the Semi-Structured Assessment for Drug Dependence and Alcoholism. Army STARRS participants (N=11,236) were evaluated using the self-administered Composite International Diagnostic Interview Screening Scales.Measurement Lifetime self-reported suicidal behaviors (ideation, SI; planning; attempt, SA); Lifetime DSM-IV diagnoses and criteria for dependence on alcohol, cannabis, cocaine (CoD), opioid (OD), and nicotine (ND) (Yale-Penn); substance use disorder (SUD) (Army STARRS).Findings In Yale-Penn, lifetime polysubstance dependence was strongly associated with lifetime suicidal behaviors: individuals with five SDs showed increased odds ranging from OR=6.77 (95%CI=5.74-7.99) for SI to OR=3.61 (95%CI=2.7-4.86) for SA. In Army STARRS, SUD was associated with increased odds ranging from OR=2.88 (95%CI=2.6-3.19) for SI to OR=3.92 (95%CI=3.19-4.81) for SA. In Yale-Penn, we identified multivariate gene–environment interactions (Bayes factors, BF > 0) of SI with respect to a gene cluster on chromosome 16 (LCAT, p=1.82×10−7; TSNAXIP1, p=2.13×10−7; CENPT, p=2.32×10−7; PARD6A, p=5.57×10−7) for OD (BF=12.2), CoD (BF=12.1), ND (BF=9.2), and polysubstance dependence (BF=2.1).Conclusions Comorbidity of multiple SDs is a significant suicide risk factor and heritability of suicidal behaviors is partially moderated by multivariate gene interactions.Competing Interest StatementDr. Kranzler is a member of the American Society of Clinical Psychopharmacologys Alcohol Clinical Trials Initiative, which for the past three years was supported by AbbVie, Alkermes, Amygdala Neurosciences, Arbor, Ethypharm, Indivior, Lilly, Lundbeck, Otsuka, and Pfizer. Dr. Kranzler is paid for his editorial work on the journal Alcoholism: Clinical and Experimental Research. Drs. Kranzler and Gelernter are named as inventors on PCT patent application #15/878,640 entitled: "Genotype-guided dosing of opioid agonists,” filed January 24, 2018. Dr. Murray Stein is paid for his editorial work on the journals Biological Psychiatry and Depression and Anxiety, and the health professional reference Up-To-Date. Drs. Polimanti and Gelernter are paid for their editorial work on the journal Complex Psychiatry. The other authors declare no competing interests.Funding StatementThis study was supported by the American Foundation for Suicide Prevention (YIG-1-109-16), the National Institute on Drug Abuse (R21 DA047527), and the Veterans Affairs National Center for Posttraumatic Stress Disorder Research. The Yale-Penn cohort was supported by multiple grants from the National Institutes of Health (R01 DA12690, R01 AA11330, and R01 AA017535). Army STARRS was sponsored by the Department of the Army and funded under U01MH087981 (2009-2015) with NIMH.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData generated are included in the manuscript and the supplemental material.